Puma Biotechnology (PBYI) depends on one product. It has weak fundamentals and has struggled to develop gross sales.
PBYI inventory has surged 91% over the previous yr, pushed by technical momentum and speculative buying and selling spikes.
Regardless of technical “Purchase” alerts, analyst sentiment is combined, with most ranking PBYI as “Maintain” or “Promote.”
With stagnant income, declining earnings, and just one product, PBYI lacks compelling long-term funding attraction.
Valued at $303 million, Puma Biotechnology (PBYI) is a small most cancers biotech whose solely marketed product, Nerlynx (neratinib) was launched in the US for the remedy of early stage HER2-positive breast most cancers in sufferers who’ve been beforehand handled with Roche’s Herceptin-based adjuvant remedy. The drug was additionally permitted within the European Union.
In the meantime, a number of further research on Nerlynx focusing on various kinds of breast most cancers affected person populations in addition to different forms of most cancers are at the moment underway. Puma markets Nerlynx within the U.S. and has a number of sub-licenses in numerous areas exterior the U.S. to commercialize Nerlynx in worldwide markets.
I discovered as we speak’s Chart of the Day through the use of Barchart’s highly effective screening capabilities to kind for shares with the very best technical purchase alerts; superior present momentum in each power and path; and a Pattern Seeker “purchase” sign. I then used Barchart’s Flipcharts function to evaluate the charts for constant worth appreciation. PBYI checks these bins. For the reason that Pattern Seeker signaled a brand new “Purchase” on Dec. 9, the inventory has gained 8.24%.
www.barchart.com
Creator’s Be aware: Be aware on the chart above that within the final 6 months there have been two spikes in each quantity and worth. This is perhaps an indication of a takeover. These spikes appear to coincide with gross sales by Michael Patrick Miller, a director of Puma and several other different biopharma corporations.
Editor’s Be aware:The technical indicators beneath are up to date reside through the session each 20 minutes and may subsequently change every day because the market fluctuates. The indicator numbers proven beneath subsequently might not match what you see reside on the Barchart.com web site once you learn this report. These technical indicators type the Barchart Opinion on a specific inventory.
Puma Biotechnology scored a brand new 52-week excessive of $6.27 on Dec. 29.
PBYI has a Weighted Alpha of +59.22.
Puma has a 100% “Purchase” opinion from Barchart.
The inventory gained 91.05% over the previous yr.
PBYI has its Pattern Seeker “Purchase” sign intact.
The inventory not too long ago traded at $6.02 with a 50-day shifting common of $5.32.
Puma made 16 new highs and gained 18.24% within the final month.
Relative Power Index (RSI) is at 64.32.
There’s a technical help degree round $5.95.
$303 million market capitalization.
8.23x trailing price-earnings ratio.
Income is anticipated to be down by 3.90% this yr and down one other 0.68% subsequent yr.
Earnings are estimated to lower 11.59% this yr and reduce an extra 20.29% subsequent yr.
Wall Avenue analysts tracked by Barchart have given 2 “Maintain” and 1 “Promote” opinions on the inventory with worth targets between $2 and $5.
Worth Line ranks the inventory “Common.”
CFRA’s MarketScope Advisor charges the inventory as “Purchase.”
Morningstar thinks with the inventory’s latest runup, it’s 8% overvalued.
192 traders following the inventory on Motley Idiot assume it can beat the market, whereas 219 assume it gained’t.
11,990 traders are monitoring the inventory on Searching for Alpha, which charges the inventory a “Maintain.”
Shorth curiosity is low at 6.81% of the float.
Particular person traders are cautious about this inventory, and I’ll need to agree with them. Though the corporate has had regular gross sales of between $225 million and $250 million for a number of years, it appears to have just one marketable product and has proven no development. This isn’t an funding, and it seems any worth motion has been brief lived and speculative. There are many higher investments elsewhere.
Further disclosure: The Barchart Chart of the Day highlights shares which are experiencing distinctive present worth appreciation. They aren’t meant to be purchase suggestions as these shares are extraordinarily risky and speculative. Do you have to determine so as to add one in every of these shares to your funding portfolio it’s extremely recommended you comply with a predetermined diversification and shifting cease loss self-discipline that’s constant along with your private funding danger tolerance.
On the date of publication, Jim Van Meerten didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All info and knowledge on this article is solely for informational functions. This text was initially printed on Barchart.com
